Quercetin and the Senolytic Revolution: The D+Q Protocol Explained

87% of Your Senescent Cells Survived Your Last Supplement Protocol

That's not a precise statistic — it's the approximate reality for anyone taking standard quercetin capsules and expecting senolytic activity. At ~1% oral bioavailability, a 1000mg capsule delivers roughly 10mg to circulation. BCL-xL inhibition in senescent cells requires substantially more.

The senolytic story is real. The published human trials are real. But the gap between "taking quercetin" and "running a senolytic protocol" is wider than most supplement marketing suggests. Here's how the actual science works.

Quercetin

The Zombie Cell Problem

Cellular senescence is one of the primary hallmarks of ageing. When cells accumulate sufficient DNA damage or reach their replicative limit, they enter permanent cell-cycle arrest — they stop dividing but refuse to die. These senescent cells develop a Senescence-Associated Secretory Phenotype (SASP), pumping out inflammatory cytokines (IL-6, IL-1b, TNF-a), chemokines, and tissue-degrading proteases.

In youth, the immune system clears senescent cells efficiently. With age, accumulation outpaces clearance. The secretory load builds. The result is inflammaging — the chronic low-grade inflammation underlying most age-related diseases.

Could we simply kill these cells off? That was James Kirkland's question at Mayo Clinic in 2015.

The Mayo Clinic Discovery

^[5]

Kirkland's group identified that senescent cells depend on specific pro-survival pathways — SCAPs (Senescent Cell Anti-Apoptotic Pathways) — to resist their own toxic environment. Target those pathways, and senescent cells selectively self-destruct while healthy cells are unaffected.

The D+Q combination emerged from systematic screening:

• Dasatinib inhibits multiple tyrosine kinases (Src, ephrin, PI3K) that senescent cells exploit
• Quercetin inhibits BCL-xL and PI3K/AKT pro-survival signalling

Neither compound alone matches the combination. The mechanisms are complementary — covering different senescent cell subpopulations in different tissues. Dasatinib hits senescent preadipocytes harder; Quercetin is more effective against senescent endothelial cells and certain fibroblasts.

The Human Trial Evidence

This is where D+Q separates itself from every other "senolytic" compound. Published human data.

Hickson et al. (2019) — First Human Senolytic Trial

^[1]

Nine patients with diabetic kidney disease. D+Q (100mg Dasatinib + 1000mg Quercetin) for 3 consecutive days. Skin and adipose biopsies taken 11 days post-treatment:

• Significant reduction in p16INK4A+ senescent cells
• Reduced SASP cytokine secretion
• First proof-of-concept that senolytics selectively clear human senescent cells

Small sample, no control group — but the biopsies showed the mechanism working in living humans.

Justice et al. (2019) — Idiopathic Pulmonary Fibrosis

^[2]

Fourteen IPF patients received three D+Q cycles over 3 weeks. IPF is progressive and fatal — there's no effective treatment. Results showed improved physical function (6-minute walk test, 4-metre gait speed). Functional improvement in a disease with no treatment options is a meaningful signal.

Gonzales et al. (2023) — Mild Alzheimer's Disease

^[3]

Five patients. Nature Medicine publication. D+Q over 12 weeks. The trial demonstrated that D+Q crosses the blood-brain barrier — measurable in cerebrospinal fluid — and reduces CNS senescence markers. Feasibility trial, not outcomes trial, but establishing BBB penetration was the critical question.

Mayo 2025 — Alzheimer's Risk Population

^[4]

The most recent published data. Older adults at elevated Alzheimer's risk received 100mg Dasatinib + 1250mg Quercetin for 2 consecutive days every 2 weeks, over 12 weeks.

• Safety: No serious adverse events attributed to D+Q
• Functional signals: Preliminary improvements in gait and certain cognitive domains
• Biomarkers: Trends toward reduced senescence markers

This trial cemented the pulsed dosing protocol now standard across senolytic research.

Fisetin

Why Pulsed, Not Daily?

This is the single most misunderstood aspect of senolytic dosing.

Senescent cells are quiescent. They're not proliferating — they're sitting there secreting inflammatory signals. You don't need continuous drug exposure to kill them. You need a peak plasma concentration high enough to trigger apoptosis:

1. High-dose pulse triggers apoptosis in susceptible senescent cells
2. Cleared cells take weeks to months to re-accumulate
3. Continuous daily dosing would increase off-target effects without adding senolytic benefit
4. Pulsed dosing matches the biology of senescent cell turnover

"1000mg Quercetin daily" is an anti-inflammatory regimen. It is NOT a senolytic regimen. Different dose, different schedule, different mechanism, different outcome.

The Bioavailability Elephant in the Room

Standard Quercetin aglycone has approximately 1% oral bioavailability. Of 1000mg consumed, ~10mg reaches circulation. For daily anti-inflammatory use, even this modest amount provides benefit through gut-local effects and accumulated tissue levels.

For senolytic activity? 10mg systemic Quercetin won't inhibit BCL-xL in tissues. The D+Q trials used research-grade formulations with enhanced absorption.

If you're spending money on quercetin supplements and using the standard aglycone form, most of your investment is passing through unabsorbed. For senolytic applications, bioavailability-enhanced forms aren't optional — they're essential.

Daily Quercetin: The Non-Senolytic Use Case

At 500–1000mg/day of an enhanced-bioavailability form, quercetin provides substantial benefits entirely separate from senolytic activity:

• Allergy/histamine control: Mast cell stabilisation comparable to OTC antihistamines
• Exercise performance: Meta-analyses show modest VO2max improvements
• Blood pressure: 3–5 mmHg reduction in hypertensive individuals
• Anti-inflammatory: Reduced CRP, IL-6, TNF-a in chronic inflammation
• Mitochondrial biogenesis: AMPK/SIRT1/PGC-1a activation supports new mitochondrial production
• Zinc ionophore: Transports zinc intracellularly for antiviral effects

This is a different use case — continuous support, not pulsed clearance. Both are valid. They're just not the same thing.

The Dasatinib Access Problem

Dasatinib is a prescription tyrosine kinase inhibitor for chronic myeloid leukaemia. Using it for senolytic purposes requires:

• Off-label physician prescription (longevity-oriented physicians can prescribe)
• Baseline bloodwork (CBC, liver enzymes)
• Understanding of side effects (GI effects, potential myelosuppression)

Quercetin alone has senolytic activity, but the D+Q synergy is substantially greater. Some practitioners use Fisetin as a natural-only alternative — it has stronger standalone preclinical senolytic evidence, though without D+Q's human trial validation.

Practical Protocol Considerations

Prerequisites for D+Q:

• Typically age 50+ (senescent cell accumulation is age-dependent)
• Baseline bloodwork (hs-CRP, CBC, metabolic panel)
• Physician oversight for Dasatinib prescription
• Bioavailability-enhanced Quercetin (Phytosome preferred)

Standard protocol (adapted from Mayo Clinic trials):

• Day 1: 100mg Dasatinib + 1250mg Quercetin (Phytosome form)
• Day 2: 100mg Dasatinib + 1250mg Quercetin
• Repeat every 2–4 weeks
• Monitor biomarkers for 3–6 months, reassess

What NOT to do:

• Daily 1250mg dosing (no added benefit, increased off-target risk)
• Single-day dosing (2-day pulse appears more effective in trial data)
• Dasatinib without physician oversight (meaningful side effect profile)
• Standard quercetin aglycone for senolytic dosing (insufficient bioavailability)

The Future of Senolytics

D+Q established that human senolytic intervention is possible and safe in small trials. The field is moving toward:

• Newer selective senolytics (UBX0101, UBX1325) — purpose-built senolytic drug candidates
• Natural senolytic optimisation — Fisetin, Piperlongumine combinations
• Senomorphics — compounds that suppress SASP without killing cells
• Personalised timing based on biological age markers and senescent cell burden assays

Quercetin — inexpensive, safe, extensively studied — will likely remain central to human senolytic protocols. But the bioavailability form you choose will determine whether you're running an actual senolytic protocol or an expensive anti-inflammatory regimen.

FAQ

Is daily quercetin the same as a senolytic protocol?

No. Daily 500–1000mg provides anti-inflammatory, antihistamine, and mitochondrial benefits but does NOT achieve the peak plasma concentration required for BCL-xL inhibition and senescent cell clearance. Senolytic dosing is 1250mg pulsed for 2 days, cycled every 2–4 weeks.

Can I do the senolytic protocol without Dasatinib?

Quercetin alone has some senolytic activity, but substantially less than D+Q. Fisetin is the most common natural-only alternative — stronger preclinical senolytic evidence than standalone quercetin, though lacking D+Q's human RCT data.

At what age should I start senolytic protocols?

Most senolytic research enrolls participants 50+. Senescent cell accumulation is age-dependent — younger individuals typically have lower burden and less to clear. Baseline hs-CRP and inflammatory markers can help assess whether senolytic intervention is warranted.

What bloodwork do I need before starting D+Q?

Complete blood count (CBC), comprehensive metabolic panel (liver enzymes, kidney function), and hs-CRP at minimum. Dasatinib can cause myelosuppression, so monitoring blood counts is essential.

Is Quercetin Phytosome worth the premium price?

For daily anti-inflammatory use, EMIQ or Quercetin + Bromelain may be sufficient at lower cost. For senolytic protocols where bioavailability is critical, Phytosome (Quercefit) is the best-validated option. The ~20x bioavailability improvement justifies the cost when tissue-level concentrations matter.

Related Research

• Astaxanthin: The First Natural Supplement With 10%+ Lifespan Extension
• CoQ10 and Statins: Why Every Statin User Should Be Supplementing
• Autophagy Optimization: The Cell's Self-Cleaning Protocol

Scientific References

1. Hickson LJ, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin. EBioMedicine (2019). PMID 31542391

2. Justice JN, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine (2019). PMID 30616998

3. Gonzales MM, et al. Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. Nature Medicine (2023). PMID 37697045

4. Mayo Clinic team. Senolytics in older adults at risk for Alzheimer's disease — pilot study. eBioMedicine (February 2025). PMID 40006896

5. Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. Journal of Internal Medicine (2020). PMID 32686219